Centre Paul Strauss
Centre Paul Strauss
Strasbourg, France27 results · Page 1 of 2
Clinical trials
Swipe the table sideways for more columns.
| Trial | Conditions | Status | Phase | Updated | More info | NCT ID |
|---|---|---|---|---|---|---|
| Study Aiming to Compare the Plasma Exposure of the Payload (Free-DXd) in Patients Treated by T-DXd for Locally Advanced or Metastatic Breast Cancer According to Their BMI. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Phase 4 | 2026-10-08 | NCT07195344 | |
| Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention | Neoplasms by Site, brain disorder, central nervous system cancer, central nervous system disorder, neoplasm, nervous system disorder | Recruiting | Not applicable | 2026-10-08 | NCT06599879 | |
| Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer | Breast Cancer Recurrent | Active, not recruiting | Phase 3 | 2026-09-03 | NCT03820830 | |
| Elacestrant + Everolimus in Patients ER+/HER2-, ESR1mut, Advanced Breast Cancer Progressing to ET and CDK4/6i. | Advanced Breast Cancer; ER-positive Breast Cancer; ESR1 Gene Mutation; HER2-negative Breast Cancer | Recruiting | Phase 3 | 2026-08-24 | NCT06382948 | |
| Tracking Triple-negative Breast Cancer Evolution Through Therapy | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Active, not recruiting | Not applicable | 2026-08-03 | NCT03077776 | |
| Identification of Innovative Biomarkers to Predict Outcomes in Hepatocellular Carcinoma Treated With Tremelimumab and Durvalumab | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, adenocarcinoma, carcinoma, epithelial neoplasm, hepatocellular carcinoma, liver disorder, neoplasm | Recruiting | Not applicable | 2026-07-23 | NCT06796114 | |
| Systematic Radioiodine Administration Versus Decision of Radioiodine Treatment Guided by a Post-operative Work-up | Head and Neck Neoplasms, Neoplasms by Site, endocrine system disorder, malignant endocrine neoplasm, neoplasm, thyroid gland disorder, thyroid tumor | Recruiting | Phase 3 | 2026-06-25 | NCT04290663 | |
| Arm Swelling Occurence in Breast Cancer Patients With Nodal Radiotherapy: Impact of Informing Them of AI-predicted Risk | Neoplasms by Site, Skin and Connective Tissue Diseases, Unilateral Breast Neoplasms, breast disorder, breast neoplasm, neoplasm, skin disorder | Recruiting | Not applicable | 2026-05-19 | NCT07187726 | |
| Stereotactic Body Radiation Therapy (SBRT) Efficiency and Toxicity in Liver Cancer | Digestive System Diseases, Digestive System Neoplasms, Liver Neoplasms, Neoplasms by Site, liver cancer, liver disorder, neoplasm | Active, not recruiting | Not applicable | 2026-03-30 | NCT03408665 | |
| Testing Mitazalimab in Combination With Standard Chemotherapy in Immunotherapy Resistant Advanced Biliary Tract Cancers | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, neoplasm | Not yet recruiting | Phase 2 / Phase 3 | 2026-02-27 | NCT07437287 | |
| PD-1 Inhibitor and Chemotherapy With Concurrent Irradiation at Varied Tumour Sites in Advanced Non-small Cell Lung Cancer | Neoplasms by Site, Thoracic Neoplasms, bronchial neoplasm, bronchogenic carcinoma, lung disorder, lung neoplasm, neoplasm, non-small cell lung carcinoma, respiratory system disorder, respiratory tract neoplasm | Active, not recruiting | Phase 3 | 2026-02-25 | NCT03774732 | |
| EULAT Eradicate GBC | Biliary Tract Neoplasms, Digestive System Diseases, Digestive System Neoplasms, Neoplasms by Site, biliary tract disorder, cholelithiasis, gallbladder disorder, gallbladder neoplasm, neoplasm | Recruiting | Not stated | 2026-02-18 | NCT06192719 | |
| Randomized, Open Label, Clinical Study of the Targeted Therapy, Palbociclib, to Treat Metastatic Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, estrogen-receptor positive breast cancer, neoplasm, skin disorder | Active, not recruiting | Phase 3 | 2026-02-12 | NCT02947685 | |
| Role of Sodium-glucose Linked Transporter 2 (SGLT2) and Its Inhibitor Over CARdiotoxicity Induced by Anthracyclines and Breast Cancer Tumorigenesis SCARA-B | Cardiotoxicity, Chemically-Induced Disorders, Drug-Related Side Effects and Adverse Reactions, Neoplasms by Site, Pathologic Processes, Pathological Conditions, Signs and Symptoms, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, cardiovascular disorder, heart disorder, injury, neoplasm, radiation injury, skin disorder | Recruiting | Not stated | 2026-02-04 | NCT06443645 | |
| Simultaneous Integrated Boost FDOPA Positron Emission Tomography (PET) Guided in Patients With Partially- or Non-operated Glioblastoma | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, astrocytoma (excluding glioblastoma), epithelial neoplasm, glioblastoma, glioma, neoplasm, neuroepithelial neoplasm, primitive neuroectodermal tumor | Recruiting | Phase 2 | 2026-02-04 | NCT05653622 | |
| Radiotherapy Omission in Low Risk Ductal in Situ Carcinoma Breast | Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Ductal, Lobular, and Medullary, Skin and Connective Tissue Diseases, adenocarcinoma, breast cancer, breast carcinoma in situ, breast disorder, breast neoplasm, carcinoma, ductal breast carcinoma in situ, epithelial neoplasm, in situ carcinoma, neoplasm, skin disorder | Active, not recruiting | Not applicable | 2026-01-23 | NCT03878342 | |
| Trial of FOLFIRI + Zimberelimab + Domvanalimab vs FOLFIRI With a Hybrid Synthetic Control Arm in Second Line Treatment of Neuroendocrine Carcinoma of Gastro-enteropancreatic or Unknown Origin (REWENEC 01) | Neoplasms by Histologic Type, Neoplasms, Germ Cell and Embryonal, Neoplasms, Nerve Tissue, adenocarcinoma, carcinoma, epithelial neoplasm, neoplasm, neuroendocrine carcinoma, neuroendocrine neoplasm, primitive neuroectodermal tumor | Not yet recruiting | Phase 2 | 2026-01-13 | NCT07337447 | |
| Capecitabine Plus Pembrolizumab in Patients With Triple Negative Breast Cancer After Chemo-immunotherapy and Surgery | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, neoplasm, skin disorder, triple-negative breast carcinoma | Recruiting | Phase 2 | 2025-11-17 | NCT05973864 | |
| Long-term Cognitive and Functional Impact of Proton-therapy or Modern Fractionated Radiotherapy in Cavernous Sinus Meningioma: An Open-label Randomized 1:1 Phase III Study | Cognition Disorders, Cognitive Dysfunction, cavernous sinus meningioma, cognitive disorder, psychiatric disorder | Recruiting | Not applicable | 2025-09-29 | NCT05895344 | |
| Study of Immunotherapy in Combination With Chemotherapy in HER2-negative Inflammatory Breast Cancer | Neoplasms by Site, Skin and Connective Tissue Diseases, breast disorder, breast neoplasm, inflammatory breast carcinoma, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-09-12 | NCT03515798 | |
| Combined Apalutamide, Radiotherapy, and LHRH Agonist in Prostate Cancer Patients After Prostatectomy | Genital Diseases, Male Urogenital Diseases, Neoplasms by Site, Urogenital Diseases, Urogenital Neoplasms, male reproductive organ cancer, male reproductive system disorder, neoplasm, prostate cancer, prostate disorder | Active, not recruiting | Phase 3 | 2025-07-30 | NCT04181203 | |
| Maintenance With Olaparib or Selumetinib + Durvaluma for m-PDAC Guided by BRCAness and KRAS Status. | Metastatic Pancreatic Adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT04348045 | |
| OSE2101+FOLFIRI, or FOLFIRI Maintenance After FOLFIRINOX-based Induction Therapy in Advanced or Metastatic PDAC | Neoplasm Metastasis, Neoplastic Processes, Pathologic Processes, Pathological Conditions, Signs and Symptoms, metastatic malignant neoplasm, neoplasm, pancreatic ductal adenocarcinoma | Active, not recruiting | Phase 2 | 2025-07-25 | NCT03806309 | |
| Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy. | Advanced Biliary Tract Carcinoma | Active, not recruiting | Phase 2 | 2025-07-23 | NCT03704480 | |
| Chemotherapy-free Trastuzumab and Pertuzumab in HER2-positive Breast Cancer: FDG-PET Response-adapted Strategy. | Neoplasms by Site, Skin and Connective Tissue Diseases, breast cancer, breast disorder, breast neoplasm, neoplasm, skin disorder | Active, not recruiting | Phase 2 | 2025-04-23 | NCT03161353 |